FDA OOPD grants orphan drug designation to Alitair’s Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties. Alitair President and CEO William Howard said, "We are excited

Ken’s Story

My name is Ken and I have been diagnosed with Bronchiectasis, after years of chest problems. Ever since I was a child, I struggled with chest problems, including whooping cough and measles etc, and my mother told me, that a doctor had said that I had a smokers cough at the age of 4, but

Danielle’s story

My story, Danielle Hudson When I was 18 months old I had a chest infection that turned to double pneumonia and I was in an oxygen tent for 4 days. The antibiotics I was given at this time, tetracycline, left my teeth discoloured. I was in hospital for a year, which was fairly typical for